Pomegranate skin extract for treating fatty liver

• US 10,046,017 B2
• Filed: 01/09/2014
• Issued: 08/14/2018
• Est. Priority Date: 01/09/2014
• Status: Active Grant

• Current Assignee: Societe des Produits Nestle SA (Nestle SA)
• Original Assignee: Nestec SA (Nestle SA)
• Inventors: Szeto, Ignatius, Zhang, Peifang, Zhang, Weiguo, Wang, Junkuan, Chou, Chieh Jason
• Primary Examiner(s): Mi, Qiuwen
• Application Number:
  US15/109,723
• Publication Number:
  US 20160324907A1
• Time in Patent Office: 1,678 Days
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals.

Claims

1. A method for inhibiting body weight gain and treating fatty liver disease in a human having the fatty liver disease and a characteristic selected from the group consisting of (i) a body mass index equal to or above 25, (ii) the fatty liver disease is non-alcoholic fatty liver disease, and (iii) a combination thereof, the method comprising administering a composition comprising pomegranate skin extract to the human.

2. The method of claim 1, wherein the composition comprises at least 30% of punicalagin.

3. The method of claim 1, wherein the composition is administered in an amount that inhibits inhibiting steatosis.

4. The method of claim 1, wherein the composition is administered in an amount that decreases the expression level of liver function markers ALT and AST.

5. The method of claim 1, wherein the human has a high fat diet.

6. The method of claim 1, wherein the human has a body mass index equal to or above 25.

7. The method of claim 1, wherein the human is a patient suffering from non-alcoholic fatty liver disease.

8. The method of claim 1, wherein the composition is administered orally.

9. The method of claim 1, wherein the oral administration is performed via a route selected from the group consisting of foods, drinks, dietary supplements and pharmaceutical compositions.

10. The method of claim 1, wherein composition is administered at a dose from 1 to 50 mg/kg/day.